Cutaneous lymphomas: A review

Kutanöz lenfomalar: Derleme

Denis R. Miyashiro¹, *Jose Antonio Sanches¹

¹Department of Dermatology, University of São Paulo School of Medicine, Brazil
Corresponding author: Dr. Jose Antonio Sanches, Department of Dermatology, University of São Paulo School of Medicine, São Paulo, Brazil
E-mail: jasanches@usp.br
Received/Accepted: April 27, 2015/May 22, 2015
Conflict of interest: There is not a conflict of interest.

SUMMARY
Skin may be affected by non-Hodgkin lymphomas, and it is the second most frequently involved extranodal organ, after the gastrointestinal tract. Cutaneous lymphomas may originate from T, B, or NK lymphocytes. Diagnosis is difficult, and knowledge of these diseases is important to ensure their detection and adequate treatment and follow-up. Clinical picture is heterogeneous, and histology is essential to confirm the diagnosis. The classification is given by the correlation between clinical findings, histology and immunophenotyping. Therapeutic options include skin-directed therapies, immunomodulatory or low-dose immunosuppressive drugs. Rare cases of aggressive disease require systemic multidrug chemotherapy. The purpose of this review is to describe the ontogeny of T, B and NK lymphocytes, and to detail the most accepted classification of cutaneous lymphomas, proposed by the World Health Organisation and European Organisation for Research and Treatment of Cancer. Treatment of cutaneous lymphomas will be briefly discussed.

Keywords: Cutaneous lymphomas, classification, treatment

ÖZET

Anahtar sözcükler: Kutanöz lenfomalar, sınıflandırma, tedavi

INTRODUCTION
The skin may be affected either primarily or secondarily by lymphoproliferative processes, due to infiltration of neoplastic cells originating from other anatomical sites. Primary cutaneous lymphomas are diagnosed when there is exclusive involvement of the skin, with no evidence of lymphoproliferative disease at other sites at the time of diagnosis. If there is evidence of extracutaneous disease, the skin is considered to be secondarily involved¹.

Primary cutaneous lymphomas are non-Hodgkin lymphomas. The skin is the second most frequently involved extranodal organ, after the gastrointestinal tract. Cutaneous lymphomas may originate from T, B, or NK lymphocytes. The classification of cutaneous lymphomas is given by the correlation between clinical findings, histology, immunophenotyping², ³. Due to the different clinical behaviors of their systemic counterparts, the European Organisation for Research and Treatment
of Cancer (EORTC), in 1997, and the World Health Organisation (WHO), in 2001, classified cutaneous lymphomas as separate entities of nodal lymphomas. However, there were controversies regarding cutaneous T-cell lymphomas (CTCL) (other than mycosis fungoides (MF), Sézary syndrome (SS), and CD30+ lymphoproliferative disorders), as well as controversies regarding the classification and terminology of cutaneous B-cell lymphomas (CBCL). In 2005, a consensus among members of the EORTC and WHO was published, which provided a new classification of primary cutaneous lymphomas and other systemic diseases that often affect the skin, such as adult T-cell leukemia/lymphoma (ATLL) and CD4+CD56+ hematodermic neoplasm (blastic NK-cell lymphoma). This classification facilitates the distinction of indolent and aggressive forms of cutaneous lymphomas, thereby directing the treatment and follow-up of these patients (Table 1).

Table 1: Classification of cutaneous lymphomas.

<table>
<thead>
<tr>
<th>Cutaneous T-cell and NK-cell lymphomas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mycosis fungoides</td>
</tr>
<tr>
<td>MF variants and subtypes</td>
</tr>
<tr>
<td>Folliculotrophic MF</td>
</tr>
<tr>
<td>Pagetoid reticulosis</td>
</tr>
<tr>
<td>Granulomatous slack skin</td>
</tr>
<tr>
<td>Sézary syndrome</td>
</tr>
<tr>
<td>Adult T-cell leukemia/lymphoma</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Primary cutaneous CD30 + lymphoproliferative disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary cutaneous anaplastic large cell lymphoma</td>
</tr>
<tr>
<td>Lymphomatoid papulosis</td>
</tr>
<tr>
<td>Subcutaneous panniculitis-like T-cell lymphoma</td>
</tr>
<tr>
<td>Extranodal NK/T-cell lymphoma, nasal type</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Provisional entities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary cutaneous aggressive epidermotropic CD8 + T-cell lymphoma</td>
</tr>
<tr>
<td>Cutaneous γ/δ T-cell lymphoma</td>
</tr>
<tr>
<td>Primary cutaneous CD4 + small/medium-sized pleomorphic T-cell lymphoma</td>
</tr>
<tr>
<td>Primary cutaneous peripheral T-cell lymphoma, unspecified</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cutaneous B-cell lymphomas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary cutaneous follicle center lymphoma</td>
</tr>
<tr>
<td>Primary cutaneous marginal zone B-cell lymphoma</td>
</tr>
<tr>
<td>Primary cutaneous diffuse large B-cell lymphoma, leg type</td>
</tr>
<tr>
<td>Primary cutaneous diffuse large B-cell lymphoma, other</td>
</tr>
<tr>
<td>Intravascular large B-cell lymphoma</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Precursor hematologic neoplasm</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4+/CD56 + hematodermic neoplasm (blastic NK-cell lymphoma)</td>
</tr>
</tbody>
</table>

**Epidemiology**

An annual incidence rate of new cases of cutaneous lymphomas of 1 in 100,000 people is estimated to occur in the United States. Of primary cutaneous lymphomas, 75% are T-cell lymphomas, 25% are B-cell lymphomas, and less than 1% are NK-cell lymphomas. Males are more affected than females, with a male to female ratio of 2 or 3 to 1. The mean age at diagnosis is between 50 and 60 years of age; however, the disease may also occur in childhood.

**Ontogeny of lymphocytes**

Lymphocytes originate from bone marrow stem cells. T-cells produced in the bone marrow migrate to the thymus, where they interact with the thymic stroma, leading to maturation and expression T-cell lineage markers. These lymphocytes are CD3+CD2+CD5+CD7+, and they can also be CD4+CD8-, CD4-CD8+, or CD4-CD8-. T-cell receptors (TCRs) may be composed by α/β or γ/δ heterodimers. Initially, TCR α/β lymphocytes have double negative
immunophenotypes for CD4 and CD8. Then, they express both markers (CD4+CD8+). Finally, differentiation occurs between the CD4+CD8-helper and the CD4-CD8+ cytotoxic T lymphocytes, where the TCR γ/δ cytotoxic lymphocytes are CD4-CD8+. Upon leaving the thymus, these naive lymphocytes circulate into the bloodstream or migrate to peripheral lymphoid organs. When exposed to antigens originating from the skin, they express markers on their surface. This leads to a migration to the skin, as well as participation in its immune system.

B lymphocytes are produced and undergo maturation in the bone marrow. They then migrate to secondary lymphoid organs, such as the spleen, lymph nodes, or mucosa, or stay in the bone marrow itself. When exposed to antigens, B lymphocytes can migrate to other organs. Initially, lymph nodes are arranged in primary lymphoid follicles, which are composed of centroblasts (progenitor cells) and are not presented to antigens. Once these are presented to antigens, they turn into secondary lymphoid follicles, with a clearer central zone (the germinat center), a darker peripheral zone (the mantle zone) and a thinner zone surrounding the mantle zone (the marginal zone). Centroblasts undergo maturation and migrate from the germinal center to the mantle zone, turning into centrocytes. This maturation process occurs simultaneously with the somatic hypermutation mechanism, with an intense generation of small genetic changes in the variable component (V) of immunoglobulins, allowing for a wide variation in its structure, facilitating the recognition of a wide range of antigen variations. After this process, B lymphocytes, with the aid of T helper lymphocytes, can turn into memory B-cells or plasma cells. Thus, knowledge of the lymph node structure is important in differentiating the types of B cell lymphomas.

NK lymphocytes are produced and matured in the bone marrow. Unlike B and T lymphocytes, they are part of the body’s innate immunity, without the need for prior antigen presentation; thus, they can act directly against microorganisms or tumor cells.

**Diagnosis/exams**

The diagnosis of primary cutaneous lymphomas is confirmed by a histopathology analysis, with neoplastic lymphocytes infiltrating the epidermis, dermis, and/or subcutaneous tissue. However, the immunohistochemical examination is essential to complement the classification of cutaneous lymphomas. It initially differentiates among T, B, and NK cell lymphomas and then assists in classifying among these groups. The search for clonality of the TCR gene (T lymphocytes) or the heavy chains of immunoglobulins (B lymphocytes) is performed by polymerase chain reaction (PCR) or Southern blot and allows the detection of monoclonal populations, which are highly suggestive of malignant lymphoproliferative disorders. The search for clonality is a useful tool for differentiation between reactive lymphoproliferative processes (pseudolymphomas) and lymphomas. The immunophenotyping of lymphocytes in peripheral blood is an auxiliary technique that detects malignant cells with abnormal phenotypes, as occur in Sezary syndrome (a leukemic form of cutaneous T-cell lymphoma) or in some types of adult T-cell leukemia lymphomas (ATLL). In addition to diagnostic testing, staging tests are needed, depending on the type of lymphoma and its clinical manifestations.

**Cutaneous T-cell lymphomas (CTCL)**

Mycosis fungoides (MF) is the most prevalent cutaneous T-cell lymphoma (CTCL), corresponding to about 50% of all cutaneous lymphomas. It is a CD4+ effector memory T-cell neoplasm. MF is the only primary cutaneous lymphoma with no primary lymph node malignancy counterpart. Indolent neoplasm with insidious progression can suffer a transformation to an aggressive large-cell lymphoma. It is composed of different clinical variants and characterized by marked epidermotropism.

**Classical MF**

Classical MF initially presents with patches and infiltrated plaques, particularly in sun-protected areas, such as the buttocks. It can eventually progress to tumorous lesions and erythroderma. In more advanced cases, tumorous lesions coexist.
with patches and plaques (Figure 1). If there are only tumorous lesions, then the possibility of a lymphoma other than MF must be considered. Eventually, MF undergoes a transformation to a large-cell lymphoma, with tumorous lesions that are unresponsive to treatment and more likely to spread and involve lymph nodes.

The density of the infiltration of neoplastic lymphocytes in the skin increases from patches to plaques and tumorous lesions, but decreases in cases of erythroderma. In cases of transformed MF, more than 25% of the cells have large and irregular cytoplasms and nuclei. Immunohistochemistry shows a positivity for CD3 (pan-T antigen) and CD4, as well as a variable loss of the maturation cell marker CD7 in neoplastic cells. Moreover, reactive CD8+T lymphocytes may infiltrate MF lesions. Rare cases of CD4-CD8+ or CD4+CD8+ MF have been reported, but they show no clinical or prognostic differences from the classical CD4+CD8- MF. Genetic alterations have been described, but there is no consensus on the mutations responsible for disease susceptibility.

Staging is described in Table 2.

Table 2: Staging of MF.

<table>
<thead>
<tr>
<th>TNMB stages</th>
<th>Skin</th>
<th>Node</th>
<th>Visceral</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1</td>
<td>Limited patches, papules and/or plaques covering &lt;10% of the skin surface</td>
<td>No clinically abnormal peripheral lymph nodes; biopsy not required</td>
<td>No visceral organ involvement</td>
</tr>
<tr>
<td>T1</td>
<td>Patch only</td>
<td>Clinically abnormal peripheral lymph nodes; dermatopathic lymphadenopathy</td>
<td>Visceral involvement (must have pathology confirmation and organ involvement should be specified)</td>
</tr>
<tr>
<td>T1</td>
<td>Patch ± plaque</td>
<td>Clone negative</td>
<td></td>
</tr>
<tr>
<td>T2</td>
<td>Patches, papules and/or plaques covering ≥10% of the skin surface</td>
<td>Clinically abnormal peripheral lymph nodes; atypical lymphocytes, preserved architecture</td>
<td></td>
</tr>
<tr>
<td>T2</td>
<td>Patch only</td>
<td>Clone negative</td>
<td></td>
</tr>
<tr>
<td>T2</td>
<td>Patch ± plaque</td>
<td>Clone positive</td>
<td></td>
</tr>
<tr>
<td>T3</td>
<td>One or more tumors (≥1cm diameter)</td>
<td>Clinically abnormal peripheral lymph nodes; partial/complete effacement of nodal architecture by atypical lymphocytes; clone positive or negative</td>
<td></td>
</tr>
<tr>
<td>T4</td>
<td>Confluence of erythema covering ≥80% body surface area</td>
<td>Clinically abnormal peripheral lymph nodes; no histologic confirmation</td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>No clinically abnormal peripheral lymph nodes; biopsy not required</td>
<td>No visceral organ involvement</td>
<td></td>
</tr>
<tr>
<td>N1</td>
<td>Clinically abnormal peripheral lymph nodes; dermatopathic lymphadenopathy</td>
<td>Visceral involvement (must have pathology confirmation and organ involvement should be specified)</td>
<td></td>
</tr>
<tr>
<td>N1a</td>
<td>Clone negative</td>
<td>Clone negative</td>
<td></td>
</tr>
<tr>
<td>N1b</td>
<td>Clone positive</td>
<td>Clone positive</td>
<td></td>
</tr>
<tr>
<td>N2</td>
<td>Clinically abnormal peripheral lymph nodes; atypical lymphocytes, preserved architecture</td>
<td>Clinically abnormal peripheral lymph nodes; partial/complete effacement of nodal architecture by atypical lymphocytes; clone positive or negative</td>
<td></td>
</tr>
<tr>
<td>N2a</td>
<td>Clone negative</td>
<td>Clone negative</td>
<td></td>
</tr>
<tr>
<td>N2b</td>
<td>Clone positive</td>
<td>Clone positive</td>
<td></td>
</tr>
<tr>
<td>N3</td>
<td>Clinically abnormal peripheral lymph nodes; partial/complete effacement of nodal architecture by atypical lymphocytes; clone positive or negative</td>
<td>Clinically abnormal peripheral lymph nodes; no histologic confirmation</td>
<td></td>
</tr>
<tr>
<td>Nx</td>
<td>Clinically abnormal peripheral lymph nodes; no histologic confirmation</td>
<td>No visceral organ involvement</td>
<td></td>
</tr>
<tr>
<td>M0</td>
<td>No visceral organ involvement</td>
<td>Visceral involvement (must have pathology confirmation and organ involvement should be specified)</td>
<td></td>
</tr>
<tr>
<td>M1</td>
<td>Visceral involvement (must have pathology confirmation and organ involvement should be specified)</td>
<td>Visceral involvement (must have pathology confirmation and organ involvement should be specified)</td>
<td></td>
</tr>
<tr>
<td>B0</td>
<td>Absence of significant blood involvement: ≤ 5% of atypical peripheral blood lymphocytes</td>
<td>Absence of significant blood involvement: ≤ 5% of atypical peripheral blood lymphocytes</td>
<td></td>
</tr>
<tr>
<td>B0a</td>
<td>Clone negative</td>
<td>Clone negative</td>
<td></td>
</tr>
<tr>
<td>B0b</td>
<td>Clone positive</td>
<td>Clone positive</td>
<td></td>
</tr>
<tr>
<td>B1</td>
<td>Low blood tumor burden: &gt; 5% of atypical peripheral blood lymphocytes</td>
<td>Low blood tumor burden: &gt; 5% of atypical peripheral blood lymphocytes</td>
<td></td>
</tr>
<tr>
<td>B1a</td>
<td>Clone negative</td>
<td>Clone negative</td>
<td></td>
</tr>
<tr>
<td>B1b</td>
<td>Clone positive</td>
<td>Clone positive</td>
<td></td>
</tr>
<tr>
<td>B2</td>
<td>High blood tumor burden: ≥ 1000/μL Sézary cells or abnormal immunophenotype with positive clone</td>
<td>High blood tumor burden: ≥ 1000/μL Sézary cells or abnormal immunophenotype with positive clone</td>
<td></td>
</tr>
</tbody>
</table>

*Abnormal peripheral lymph nodes: firm, irregular, clustered, fixed or 1.5cm or larger in diameter.

For viscera, spleen and liver may be diagnosed by imaging criteria.
The five-year survival for classical MF is 93.2 to 97.3% if less than 10% of the body surface area is affected by patches and plaques (T1); 77.6 to 93.3% if more than 10% of the body surface area is affected (T2); 27.6% if tumorous lesions exist (T3); and 37.5% in erythrodermic MF (T4). Treatment depends on the stage and clinical presentation of the disease. For localized disease manifestations of patches and plaques, topical treatment with corticosteroids or nitrogen mustard and Carmustine are effective. If the disease has been disseminated, phototherapy with UVB narrow band (UVBnb) treatment for superficial lesions or psoralen with UVA (PUVA) treatment for infiltrated plaques can be used. Isolated tumor lesions may be treated with excision or radiation. If multiple tumor lesions exist, a total skin electron beam is an effective option; however, this carries important side effects, such as the loss of all body hair, changes to nails, increased risk of squamous and basal cell carcinomas, burns, and a risk of corneal damage, making it necessary to use an intraocular protection. Refractory cases with multiple tumor lesions or transformed or erythrodermic MF may require systemic treatment. Some of the systemic treatments available include: interferon α associated with PUVA; systemic retinoids, such as bexarotene; methotrexate; pralatrexate; monochemotherapy with chlorambucil, associated with prednisone; liposomal doxorubicin; and, in refractory cases, systemic polychemotherapy with gemcitabine and vinorelbine, and anthracycline-based schemes. Studies with allogeneic bone marrow transplantation have shown excellent responses, with long periods of remission. It is necessary to emphasize the importance of a careful indication of systemic treatment and, especially, systemic polychemotherapy because MF is an indolent neoplasm, with multiple and effective skin-directed therapies.

**Variants**

Folliculotropic MF predominantly affects the cephalic segment of the body with infiltrated follicular papules that converge to plaques, sometimes with acneiform aspects, keratotic plugs, cysts, and nodules, which may progress to alopecia and madarosis (Figure 2). The histology is characterized by the infiltration of the hair follicle by atypical lymphocytes with tropism, with or without associated follicular mucinosis. Inflammatory alterations, such as suppurrative folliculitis, eosinophils, and even granulomatous reactions, may also be present. Since neoplastic infiltration occurs in the hair follicle, malignant cells are located deeper in the dermis. Typically, epidermotropism is mild or non-existent (in contrast with classical MF), and syringotropism may be present. The five-year survival of folliculotropic MF is 80%. Treatment is the same as for classical MF, including skin-directed therapies, phototherapy, radiotherapy, systemic medications, and chemotherapy regimens, depending on the extent of the disease.

**Pagetoid reticulosis**

Known as Woringer-Kolopp disease, pagetoid reticulosis is an indolent and localized variant of MF. It is usually located in the limbs and is characterized by an isolated erythematous and infiltrated plaque with psoriasiform or verrucous aspects. The histological appearance is similar to that of the classical form of MF, except for the pagetoid distribution of neoplastic cells in the epidermis. Immunohistochemistry reveals a phenotype characterized by T lymphocytes (CD3+) CD4+ or, more often, CD8+. There are no reports of extracutaneous dissemination or death from pagetoid reticulosis. Radiotherapy or surgical excision may lead to long periods of remission. Other therapeutic options include topical treatment with nitrogen mustard or corticosteroid.

**Granulomatous slack skin**

Granulomatous slack skin is a rare variant of MF, with just over 40 cases described in the literature. It typically begins with sarcoid-infiltrated papules and plaques, usually affecting fold regions, such as the axillary and groin areas. The disease progresses with the formation of redundant skin areas and a lax aspect (Figure 3). Disease progression is rare, but includes reports of granulomatous infiltrates in other organs, such as the lymph nodes and the liver. Granulomatous slack skin’s histopathology...
is typical, including non-necrotizing granuloma, numerous giant cells, infiltration by atypical lymphocytes, and elastaphagocytosis. Treatment is difficult due to the recurrence of lesions. Radiotherapy is a good option for localized disease, and surgical removal may be performed on redundant skin that causes discomfort to the patient. Occasionally, granulomatous slack skin may be associated with classical MF or Hodgkin's lymphoma; thus, investigation is imperative to exclude such associations.

**Hypopigmented MF**
Hypopigmented MF commonly affects children or young adults. It is characterized by poorly defined hypochromic macules in the typical areas of classical MF, which raises the possibility of hypopigmented MF. The main differential diagnosis is pityriasis alba, which typically affects the face and the lateral parts of the arms. In hypopigmented MF lesions, the prevalence of CD8+ neoplastic lymphocytes (due to their cytotoxic action) would lead to dysfunction of the melanocytes, altering melanin production and distribution and culminating in the formation of clinically hypochromic lesions. It is an indolent disease, and treatment with topical corticosteroids, topical nitrogen mustard, or phototherapy (either UVB or PUVA) can induce clinical remission.

**Poikilodermic MF**
Poikilodermic MF is an indolent variant characterized by hypopigmented and hyperpigmented areas, telangiectasias, and atrophy, usually in double-covered areas of the trunk and flexures. There is a generalized form that affects almost all of the skin surface. Papular and scaly lesions, similar to those found in pityriasis lichenoides chronica, can be observed, and these may evolve into poikilodermic areas. Lymphomatoid papulosis can be associated in up to 18% of cases. The disease’s histopathology includes typical MF characteristics, such as
epidermotropism of atypical lymphocytes and epidermal atrophy, but with a more prominent hydropic degeneration of the basal layer, including pigmentary incontinence and telangiectatic vessels. Pautrier microabscesses are rarely observed. Neoplastic cells are predominantly CD8+42, 43. Treatment for poikilodermic MF is similar to that for classical MF.

Other
Other rare clinical manifestations of MF include the following variants: vesiculobullous, granulomatous, interstitial, syringotopic. MF with eruptive epidermoid cysts, palmaris et plantaris, solitary, anetodermic, invisible, ichthyosiform, papular, pustular, and verrucous21

Sézary syndrome (SS)
SS is a leukemic form of CTCL characterized by erythroderma (i.e., erythema and scaling in more than 80% of the body surface area—Figure 5), lymphadenopathy, and peripheral blood involvement by the neoplastic cells1

The diagnostic criteria proposed by the WHO-EORTC include a TCR gene rearrangement analysis, involving a monoclonal population of lymphocytes circulating in the peripheral blood and infiltrating the skin, as well as morphological (more than 1,000 Sézary cells per mm3) and/or immunophenotypic changes (CD4/CD8≥10, CD4+CD7≥40% CD4+CD26≥30%) in the peripheral blood (Table 3)17. Though SS was formerly considered a leukemic form of MF, there is currently controversy regarding whether the two diseases are the same or different, since MF is an effector memory CD4+T-cell neoplasm, while SS is a central memory CD4+T-cell neoplasm. In MF, malignant lymphocytes are positive for CLA and CCR4 chemokine receptors, which confer tropism to the skin, and negative for L-selectin and CCR7 receptors, which confer tropism to lymph nodes. In contrast, in SS, there is positivity for CLA, CCR4, CCR7 and L-selectin, which would explain the frequent nodal and blood involvement49. Contrary to this theory is the emergence of typical MF lesions in patients with treated SS, particularly following the improvement of erythroderma. The existence of these lesions supports the hypothesis that MF and SS may be part of a spectral disorder ranging from exclusively cutaneous diseases to those with skin, nodal, and hematological involvement.

Other clinical findings in patients with SS include: non-scarring diffuse alopecia, palmoplantar keratoderma and fissures, onychodystrophy, and variable degrees of skin infiltration. Patients may complain of intense pruritus, weight loss, fevers, and chills. These clinical findings are non-specific, and they are also found in varying frequencies in erythrodermic patients with different etiologies, highlighting the importance of extensive laboratory research seeking to determine the cutaneous and blood involvement of neoplastic cells in erythrodermic patients44, 46.

Table 3. Sézary syndrome criteria48.

| Positive clonal rearrangement of TCR by PCR or southern blot plus one of the following |
|-------------------------------------------------------------|----------------------------------|
| Sézary cell count≥1000/μL                                   |
| CD4/CD8 ratio≥10                                           |
| CD4+CD7≥40%                                                |
| CD4+CD26≥30%                                               |

The first choice of treatment is extracorporeal photopheresis, wherein, by means of apheresis, the blood lymphocytes are separated, exposed to a photosensitizer (psoralen), irradiated with UVA, and reinjected into the patient. Other treatment options include phototherapy with PUVA or UVBnb; total skin electron beam radiation; interferon α or γ; bexarotene; denileukin difitox; methotrexate; histone deacetylase inhibitors (vorinostat and romidepsin); alemtuzumab (anti-CD52 monoclonal antibody); chlorambucil combined with prednisone; systemic chemotherapy with gemcitabine and vinorelbine; and anthracycline-based schemes. As in MF, multidrug polychemotherapy for SS has partial and transient responses, with rapid relapses and minimal impact on overall survival48. Allogeneic bone marrow transplantation reports show promising results concerning the sustained remission of the disease49.
Adult T cell leukemia/lymphoma (ATLL) is a disease associated with HTLV-1, a retrovirus endemic in some parts of the world, such as Japan, Central-Western Brazil, the Caribbean, and sub-Saharan Africa. The evolution to ATLL occurs in 1 to 5% of infected patients, after years (or even decades) of infection. Considered a systemic neoplasm, ATLL manifests in cutaneous ways in about 50% of patients.

A definitive diagnosis of ATLL is given by identifying the integration of proviral DNA into the neoplastic cell genome. Histologically, the disease is characterized by the infiltration of the dermis by diffuse medium to large neoplastic cells, sometimes with marked epidermotropism (which is difficult to distinguish from MF). The immunophenotype of the malignant lymphocytes is characterized by positivity for CD3, CD4, and CD25 (interleukin-2 receptor). Treatment is based on clinical signs, with skin-directed therapy or interferon associated with zidovudine in indolent cases and with systemic multidrug therapy or bone marrow transplantation in aggressive cases. Phase 2 clinical trials with the anti-CCR4 monoclonal antibody mogamulizulab are currently being conducted, and these show promising responses thus far in refractory and aggressive cases ATLL.

Primary cutaneous CD30+ lymphoproliferative disorders

Primary cutaneous CD30+ lymphoproliferative disorders are a group of indolent cutaneous lymphomas characterized by the expression of CD30 on the cell surface. They comprise a spectrum of diseases classified between cutaneous anaplastic large T-cell lymphoma (C-ALCL) and lymphomatoid papulosis (LyP). The lesions may undergo autoregression and rarely progress to extracutaneous disease.

Cutaneous anaplastic large T-cell lymphoma (C-ALCL)

Cutaneous anaplastic large T-cell lymphoma (C-ALCL) is characterized by isolated or grouped papules, nodules, or tumors, which may ulcerate and undergo autoregression. Unlike nodal anaplastic large T-cell lymphoma (ALCL), C-ALCL has a good prognosis, with a five-year survival of 95%. The disease’s histology shows the dermal infiltration of diffuse cells with large and irregular nuclei, prominent nucleoli, and abundant cytoplasm. The neoplastic lymphocytes are CD4+,
expressing CD30 in over 75% of cells. Moreover, unlike its nodal counterpart, C-ALCL is usually negative for anaplastic lymphoma kinase (ALK), which is present in nodal anaplastic lymphomas with t (2; 5) (p23; q35). Excision and radiotherapy are the most common treatments for localized disease. In the case of multifocal lesions, low-dose methotrexate is effective. In rapidly progressive cases or extracutaneous diseases, systemic polychemotherapy regimens including doxorubicin may be used. Currently, a phase 2 study using brentuximab (anti CD30 monoclonal antibody approved for the treatment of Hodgkin’s lymphoma) is being conducted in C-ALCL cases.

**Lymphomatoid papulosis (LyP)**

Lymphomatoid papulosis (LyP) is an indolent neoplasm of CD4+ T lymphocytes, with grouped papules that progress to central necrosis and spontaneous involution, usually involving the trunk and limbs (Figure 6). Commonly, lesions in different stages of evolution can be found. The disease may be associated with MF, C-ALCL, and Hodgkin’s lymphoma. LyP manifests in four histologic types: Type A involves large and sometimes multinucleated cells, similar to the Reed-Sternberg cells of Hodgkin’s lymphoma, which infiltrate the dermis and are surrounded by inflammatory cells. Type B involves the epidermotropism of small lymphocytes with cerebriform nuclei; thus, it simulates the characteristics of MF, but with a lower expression of CD30. Type C is similar to C-ALCL, with dermal infiltration of large lymphocytes and few inflammatory cells. Finally, type D involves the epidermotropic infiltration of small/medium-sized CD8+ CD30+ lymphocytes, similar to the case of primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Diagnoses are made by clinical and pathological correlation, since the disease’s histology may be identical to that of MF or C-ALCL. Topical corticosteroids, phototherapy, or low dose methotrexate (in the case of multiple lesions) are the treatments performed; the “wait and see” strategy is also valid. The prognosis of LyP is excellent, with 100% survival at five-year follow-up.

Subcutaneous panniculitis-like T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma is an indolent CTCL with a cytotoxic atypical lymphocyte infiltration of the subcutaneous tissue. Initially, the disease involves plaques and nodules, which progress to form sclerotic and atrophic areas with retractable aspects, mainly in the lower limbs. These lesions are often indistinguishable from the lesions of inflammatory panniculitis. Hemophagocytic syndrome is a severe associated complication, indicating a worse prognosis. Histologically, pleomorphic malignant cells arranged around adipocytes in lobular patterns can be observed, as in cases of lobular panniculitis (e.g., lupus panniculitis). Immunohistochemistry reveals CD3 + T-cells, CD4 +, CD8 +, βF1+ (TCRα/β marker), TIA+, granzyme B+, and perforin +. Progression to a more aggressive disease or extracutaneous dissemination is rare, and the five-year survival is 82%. There is no standard treatment; however, there are reports of good responses to radiotherapy, systemic corticosteroids, cyclosporine, and multidrug chemotherapy in doxorubicin-based regimens.

**Figure 6: Lymphomatoid papulosis.** Grouped papules with central necrosis on the legs. Lesions in different stages of evolution can be seen.

Extranodal NK/T-cell lymphoma, nasal type Previously known as lethal midline granuloma, due to its tendency to affect the nasal and nasopharyngeal regions, this rare lymphoma has an aggressive course and is often associated with EBV infection. It presents as papules and infiltrated nodules on the face, which quickly ulcerate, leading to tissue destruction. Systemic symptoms, such as fevers and chills, may be
present, as may hemophagocytic syndrome. The disease’s histology shows a dense infiltration of neoplastic cells in the dermis and subcutaneous tissue, including angiocentric and intense inflammatory infiltrates composed by lymphocytes, histiocytes, and eosinophils. Patients with nasal-type extranodal NK/T-cell lymphoma, may exhibit an NK (75%) or T-cell phenotype (25%). The prognosis is poor, with a median survival of less than 12 months. Lactate dehydrogenase levels and B symptoms are associated with poorer prognoses. Early and aggressive treatment particularly, radiotherapy associated with systemic polychemotherapy should be instituted.

**Provisional entities**

In the WHO-EORTC classification, some types of cutaneous lymphomas do not fit into any of the well-established subtypes; thus, provisional entities were created.

**Primary cutaneous aggressive epidermotropic CD8 + cytotoxic T-cell lymphoma**

This is a rare and aggressive type of lymphoma that must be distinguished from other cutaneous lymphomas with CD8 expression, such as pagetoid reticulosis and rare cases of MF, C-ALCL, and LyP. Clinically, it presents with disseminated erythematous and violaceous infiltrated papules and nodules, as well as central necrosis. The disease rapidly disseminates to extracutaneous sites; however, nodal involvement is rare. There is marked epidermotropism of malignant lymphocytes, as well as nodular or diffuse dermal infiltration that may extend to the subcutaneous tissue. Immunohistochemistry shows the existence of CD3 + CD4-CD8+ malignant lymphocytes with high cell proliferation indexes (Ki-67). The prognosis of this variant of lymphoma is poor, with a median survival of 22 to 32 months. Treatment involves doxorubicin-based systemic chemotherapy, total skin electron beam, bexarotene and bone marrow transplantation.

**Cutaneous γ/δ T-cell lymphoma**

The T-cell receptor (TCR) heterodimer is formed by a combination of α/β or γ/δ chains. Most cutaneous lymphomas are composed of lymphocytes with a TCR α/β chain. Cytotoxic γ/δ T lymphocytes share the characteristics of the innate and adaptive immune systems, and they are present in large quantities in the skin. However, the lymphomas originating from these cells are very rare. Dermatologically, they are characterized by ulcerated and necrotic nodules, preferably in the limbs. The disease is extremely aggressive: It escalates rapidly to extracutaneous disease and can be associated with hemophagocytic syndrome. Medium to large neoplastic cells infiltrate the epidermis, dermis, and/or subcutaneous tissue, with marked angiodestruction and necrosis. Immunohistochemistry shows positivity for CD3, CD2 and CD56, along with a CD4- and CD8- phenotype. Since βF1, a TCR α/β marker, is negative, it can be concluded that these cells are TCR γ/δ. Given the median survival of 15 months, treatment via systemic mult drug chemotherapy must be instituted as soon as possible; however, the results are often disappointing.

Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma (SMPTCL) is an indolent T-cell lymphoma characterized by the infiltration of CD4+ pleomorphic T-cells, but lacking the epidermotropism evident in MF. It presents as a solitary infiltrated plaque or tumor in the face, neck, or upper trunk. Histologically, there is a prominent nodular or diffuse dermal infiltration of atypical cells, with mild and focal epidermotropism. Neoplastic cells are small- to medium-sized pleomorphic lymphocytes. Its prognosis is good: The disease tends to be limited to the skin, and the five-year survival is 75%. Often, distinguishing between primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma and T-pseudolymphomas is difficult, even with TCR gene rearrangement analysis, which may be polyclonal in up to 40% of SMPTCL patients. For this reason, Bleraminielli et al. suggested the name “cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance” for these cases. In cases of a single lesion, treatment with surgical excision or radiotherapy may be performed. There is no consensus regarding the treatment of...
disseminated lesions; however, there are reports of good responses to treatment with interferon α or cyclophosphamide. Spontaneous regression has also been described.

**Primary cutaneous peripheral T-cell lymphoma, unspecified**
This heterogeneous cutaneous lymphoma group cannot be classified into any of the well-established subtypes or provisional entities. Usually involving single or multiple nodules and tumors, the disease may progress rapidly to the lymph nodes and visceral involvement. The histology, in most cases, shows a nodular or diffuse infiltration of medium to large-sized pleomorphic CD3+CD4+CD8- lymphocytes; however, cases with CD3+CD4-CD8+, CD3+CD4-CD8-, and CD3+CD4+CD8+ phenotypes have also been described. The disease prognosis is poor, with a five-year survival of less than 20%. Treatment with systemic multidrug therapy is imperative.

**Precursor hematologic neoplasm/CD4+CD56+ hematodermic neoplasm**
Formerly known as blastic NK-cell lymphoma, this is an extremely rare neoplasm of blastic plasmacytoid dendritic cells. It is considered a systemic disease with secondary cutaneous involvement, which presents as erythematous and violaceous infiltrated plaques and nodules. Though it most often begins in the trunk region, it progresses rapidly to the lymph nodes, bone marrow, peripheral blood, and other visceral areas. The disease histology shows a diffuse and dense infiltration of medium neoplastic cells in the dermis and subcutaneous tissue, with numerous mitotic figures and few inflammatory cells. Its malignant cells are CD3+ CD4+ CD56+ CD123+.

The prognosis is poor, with a median survival of 14 months, and treatment is accomplished through systemic multidrug therapy and bone marrow transplant.

**Cutaneous B-cell lymphomas (CBCL)/Primary cutaneous follicle center lymphoma**
This is the most common subtype of CBCL, accounting for approximately 55% of CBCLs, and it is characterized by a proliferation of centrocytes and centroblasts from the germinal centers of the normal secondary lymphoid follicles. It manifests as single or multiple nodules or tumors on the face and upper trunk (Figure 7). A subtype with tumors surrounded by erythematous and infiltrated plaques in the back, was formerly known as Crosti lymphoma. It is an indolent disease, and systemic involvement is rare; however, the disease may transform into diffuse large B-cell lymphoma, with a more aggressive course. Histologically, atypical centrocytes and centroblasts, which act as diffuse or nodular infiltrates in the dermis and simulate a germinal center, have been observed. Immunohistochemistry reveals negativity for CD3 (pan-T antigen) and positivity for CD20, CD19, CD79a, and bcl6. CD10 is positive in cases of follicular patterns and negative in cases of diffuse patterns. Bcl2 is either negative or expressed by few neoplastic cells, and it is associated with a higher probability of extracutaneous involvement. The disease prognosis is very good, with a five-year survival of 95%. Local treatments with radiation therapy, excision, and intralesional corticosteroids are effective. For patients with multiple lesions or extracutaneous dissemination, anthracycline-based chemotherapy or systemic or intralesional anti-CD20 monoclonal antibodies (rituximab) can be used. If a transformation to high-grade lymphoma occurs, systemic multidrug therapy is necessary.

![Figure 7: Follicle center B-cell lymphoma. Multiple nodules on the scalp.](image-url)
burgdorferi infection in Europe\textsuperscript{102}. Clinically, the disease is characterized by erythematous and violaceous papules and nodules, located primarily on the trunk and upper limbs. Similar to follicle center lymphoma, primary cutaneous marginal-zone B-cell lymphoma may progress to more aggressive forms, such as diffuse large B-cell lymphoma\textsuperscript{1}. Its histology shows nodular and/or diffuse infiltrates in the dermis, with a darker center composed of small lymphocytes. This center is surrounded by a clearer area of medium cells with abundant cytoplasm, similar to centrocytes. There may be inflammatory cells in the interfollicular areas, thereby making the differentiation of marginal-zone B-cell lymphoma and pseudolymphomas more challenging\textsuperscript{103}. The neoplastic cells are CD20+CD19+CD10-CD79a+, bcl2+, and bcl6-; however, the reactional germinal centers are bcl6+, CD10+, and bcl2\textsuperscript{-}\textsuperscript{101, 104}. The disease prognosis is very good, with a five-year survival of 100\%\textsuperscript{1}. Treatment for single or grouped lesions can be accomplished with radiotherapy or surgical excisions. For cases associated with infection by Borrelia burgdorferi, systemic antibiotics should be introduced\textsuperscript{102}. If the disease is multifocal or extracutaneous, interferon α, chlorambucil or intralesional or systemic anti-CD20 monoclonal antibody (rituximab) can be used\textsuperscript{104-106}.

**Primary cutaneous diffuse large B-cell lymphoma, leg type**

This is an intermediate form of CBCL, which characteristically affects the lower limbs. It manifests as nodules and tumors of rapid growth in the legs, which may rapidly disseminate to the lymph nodes\textsuperscript{107, 108}. Reports of primary cutaneous diffuse large B-cell lymphoma affecting other topographies are rare. Its histology shows centroblasts and immunoblasts in a diffuse infiltrate pattern, which affect the dermis and subcutaneous tissue. Moreover, a presence of mitotic figures and a rarity of reactive T lymphocytes have been observed\textsuperscript{1,2}. Immunohistochemistry shows positivity for CD20, CD19, CD79a, bcl2, and bcl6 and negativity for CD10\textsuperscript{101, 109}. The five-year survival is 55\%, with a worse prognosis in the case of multiple lesions\textsuperscript{1, 108}. Treatment is done with an anti-CD20 monoclonal antibody (rituximab), applied either alone or in combination with radiotherapy and other chemotherapeutic drugs. Response rates are good, but relapses occur frequently\textsuperscript{99, 106, 110}.

**Primary cutaneous diffuse large B-cell lymphoma, other**

This is an intermediate form of CBCL, which includes rare cases of large B-cell lymphomas that do not belong to either primary cutaneous diffuse large B-cell lymphoma (leg type) or follicle center lymphoma. Generally, this group includes plasmablastic and anaplastic variants of diffuse large B-cell lymphomas, B-cell lymphomas rich in inflammatory T-cells and histiocytes, and cutaneous manifestations of systemic lymphomas. Clinically, variants in this group resemble follicle center and marginal zone B-cell lymphomas, with nodules and tumors affecting the head, trunk, and extremities. The disease’s five-year survival is 50\%\textsuperscript{1, 2, 111}.

**Intravascular large B-cell lymphoma**

This is a rare variant of CBCL with an intermediate prognosis. Clinically, it manifests as papules, infiltrated plaques, and telangiectasias, located predominantly on the trunk and lower limbs. The disease usually affects the central nervous system, lungs and skin\textsuperscript{112}. Histologically, large and atypical lymphocytes in the blood vessels of the dermis and subcutaneous tissue are observed; the neoplastic cells are positive for CD20, CD79a, bcl2, and bcl6, but often negative for CD10\textsuperscript{113}. The three-year survival is 22 to 56\%, depending on the presence or absence of extracutaneous disease\textsuperscript{114}. Early treatment with systemic polychemotherapy is imperative.

In conclusion; this skin is the second-most-affected extranodal site with regard to non-Hodgkin lymphomas (preceded only by the gastro-intestinal tract). Unlike nodal lymphomas, most cutaneous lymphomas are derived from T-lymphocytes; moreover, MF is the most prevalent cutaneous lymphoma. It has numerous variants, each with a different clinical manifestation and prognosis. The diagnosis of cutaneous lymphomas is difficult; thus, knowledge of these entities is important to ensure their detection, in order to perform an early diagnosis.
We highlight the need for careful evaluation prior to the use of systemic polychemotherapy in primary cutaneous lymphomas, since most of these diseases are indolent, with numerous therapeutic options, such as skin-directed therapies and immunomodulatory or low-dose immunosuppressive drugs. Systemic multidrug therapy is reserved for rare cases of aggressive disease, with rapid progression to extracutaneous involvement or refractory cases of extensive skin lesions. In addition to the deleterious side effects of polychemotherapy, patients of systemic multidrug therapy suffer partial and transient responses, with high rates of relapse and disease progression. It is also important to note that patients should be treated by a dermatologist, hematologist, oncologist, and radiation oncologist collaboratively, since a holistic approach is critical to better managing the treatment and follow-up of these patients.

REFERENCES


46. Pal S, Haroon TS. Erythroderma: A clinico-etiologic study of 90
59. Hoque SR, Child FJ, Whittaker SJ,


72. Nofal A, Abdel-Mawla MY, Assaf M, Salah E. Primary cutaneous aggressive epidermotropic


